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Abstract
Background: Permanent fatty acid translocase (FAT/)CD36 relocation has previously been shown to be related to abnormal
lipid accumulation in the skeletal muscle of type 2 diabetic patients, however mechanisms responsible for the regulation of
FAT/CD36 expression and localization are not well characterized in human skeletal muscle.
Methodology/Principal Findings: Primary muscle cells derived from obese type 2 diabetic patients (OBT2D) and from
healthy subjects (Control) were used to examine the regulation of FAT/CD36. We showed that compared to Control
myotubes, FAT/CD36 was continuously cycling between intracellular compartments and the cell surface in OBT2D
myotubes, independently of lipid raft association, leading to increased cell surface FAT/CD36 localization and lipid
accumulation. Moreover, we showed that FAT/CD36 cycling and lipid accumulation were specific to myotubes and were not
observed in reserve cells. However, in Control myotubes, the induction of FAT/CD36 membrane translocation by the
activation of (AMP)-activated protein kinase (AMPK) pathway did not increase lipid accumulation. This result can be
explained by the fact that pharmacological activation of AMPK leads to increased mitochondrial beta-oxidation in Control
cells.
Conclusion/Significance: Lipid accumulation in myotubes derived from obese type 2 diabetic patients arises from abnormal
FAT/CD36 cycling while lipid accumulation in Control cells results from an equilibrium between lipid uptake and oxidation.
As such, inhibiting FAT/CD36 cycling in the skeletal muscle of obese type 2 diabetic patients should be sufficient to diminish
lipid accumulation.
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Introduction
Intramyocellular lipid accumulation in skeletal muscle is
abnormally high in type 2 diabetes and contributes to the etiology
of the pathology [1]. Long chain fatty acid (such as palmitate)
uptake is achieved by a concert of co-existing mechanisms. These
lipids can passively diffuse, but certain membrane proteins can also
accelerate the transport. Membrane fatty acid transporters can
modulate the balance between fatty acid uptake and subsequent
storage and/or oxidation in muscle tissue. The principal muscle
fatty acid transporter FAT/CD36 (fatty acid translocase) is
involved in regulating the uptake of long-chain fatty acids into
skeletal muscle [2,3]. Abnormal increased fatty acid transport [4]
and membrane FAT/CD36 relocation [4,5] independent of
mitochondrial dysfunction result in an excessive accumulation of
intramyocellular lipid in skeletal muscle tissue of type 2 diabetic
patients. To date, little is known about FAT/CD36 regulation in
human skeletal muscle. In this tissue, the mechanisms known to
induce FAT/CD36 translocation from intracellular storage
compartments towards plasma membrane are insulin, (AMP)-
activated protein kinase (AMPK) signaling pathways and muscle
contraction [6,7].
Mature muscles possess a population of satellite cells located on
their surface. In vitro satellite cells differentiation is characterized by
withdrawal of myoblasts from the cell cycle, induction of muscle-
specific gene expression, and cell fusion into multinucleated
myotubes. After differentiation in vitro, satellite cells are composed
of two populations of cells: mature myotubes and quiescent
undifferentiated myoblasts (reserve cells) [8]. In adipocytes, FAT/
CD36 expression appeared to be closely linked to preadipocyte
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expression and localization during the differentiation of primary
human satellite cells has not been previously studied. These
primary human satellite cells, when derived from type 2 diabetic
patients, have been shown to display the majority of the defects
previously described for type 2 diabetic muscle in vivo including
defective insulin signaling pathway [10,11,12], metabolic inflexi-
bility [13,14,15] and abnormal cell surface FAT/CD36 localiza-
tion [5].
In this context, cell culture of human primary satellite cells
offers an excellent and dynamic model to study the link between
lipid accumulation and the regulation of FAT/CD36 localization.
The aim of this study was to compare FAT/CD36 regulation
between primary human satellite cells isolated from healthy
subjects and from obese type 2 diabetic patients [5] in order to
uncover new mechanisms of FAT/CD36 regulation associated
with obesity and/or type 2 diabetes.
Results
Plasma membrane FAT/CD36 and lipid accumulation are
increased in OBT2D cells
We have previously shown that lipid accumulation was
dependent upon the obesity of the donor subject and partially
due to cell surface FAT/CD36 localization [5]. We confirmed this
result by showing that palmitate-induced lipid accumulation was
significantly increased in myotubes derived from obese type 2
diabetic patients (OBT2D) compared to myotubes derived from
non-obese healthy subjects (Control) (p,0.05; Fig. 1 A). We also
confirmed cell surface localization of FAT/CD36 in OBT2D cells,
by immunofluorescence staining of FAT/CD36 in living cells (no
permeabilization) using two different antibodies raised against
FAT/CD36, a polyclonal antibody (H300) (Fig. 1 B, left panel)
and a monoclonal conjugated to alexa488 antibody (CD36-
alexa488) (Fig. 1 B, right panel). Moreover, cell surface localization
of FAT/CD36 was specifically observed in multinucleated
troponin T (TT) positive OBT2D myotubes with both antibodies
(left and right panels), with no such staining in Control cells. In
order to show that cell surface staining of FAT/CD36 was
quantitatively associated with plasma membrane relocation, we
performed fractionation experiments and prepared plasma
membrane (Mb) and post-plasma membrane (P) fractions (Fig. 1
C). Since caveolin 3 is expressed exclusively in muscle cell types
[16] and is expressed in plasma membrane microdomains, it was
used as a marker of plasma membrane fractions. We monitored
total FAT/CD36 and caveolin 3 expression in Control derived
from four different healthy subjects (1 to 4) and in OBT2D derived
from three obese type 2 diabetic patients (1 to 3) cells before
fractionation (Fig. 1 C, top panels). After fractionation (Fig. 1 C,
bottom panels), FAT/CD36 in Control (1 to 4) differentiated cells
was only detected in caveolin 3 negative P fractions. In contrast, in
OBT2D (1 to 3) differentiated cells, FAT/CD36 was found in both
P and Mb fractions.
FAT/CD36 membrane localization in OBT2D myotubes is
involved in lipid accumulation
During skeletal muscle differentiation, myoblasts exit the cell
cycle and differentiate, giving rise to a heterogeneous population of
cells. A major subpopulation consists of myotubes, quiescent
multinucleated cells expressing muscle-specific differentiation
proteins such as troponin T. A minor subpopulation of myoblasts
remains quiescent and undifferentiated [8]. Positive oil red O
staining was only observed in multinucleated Control and OBT2D
myotubes but not in reserve cells (Fig. 2 A, arrows show reserve
cells). As shown in figure 2 B (overlay of FAT/CD36, troponin T
and DAPI staining) cell surface FAT/CD36 appeared as a
punctuate staining only detected at the cell surface of troponin T
positive cells and not in reserve cells (arrows). To determine if the
specific localization of FAT/CD36 in OBT2D myotubes was due
to increased expression of FAT/CD36 during differentiation, we
monitored total FAT/CD36 expression by Western blot in two
Control (1 and 2) and two OBT2D (1 and 2) cell cultures (0, 2, 4, 6
and 8 days of differentiation) (Fig. 2 C). a-tubulin expression was
used as a loading control. OBT2D satellite cells have a normal
induction of troponin T and caveolin 3 expression during
differentiation. Total FAT/CD36 expression was already detected
in proliferative cells and was not increased during differentiation in
Control and OBT2D cells (Fig. 2 C, right panel).
Plasma membrane FAT/CD36 and lipid accumulation were
observed in differentiated OBT2D cells. To determine whether a
positive correlation between membrane FAT/CD36 and lipid
accumulation could be observed in OBT2D cells, cell surface
FAT/CD36 and oil red O co-staining was performed during
differentiation. Positive oil red O and membrane FAT/CD36 co-
staining was only detected in differentiated cells, after 4 and 8 days
of differentiation (Fig. 2 D). We next determine whether FAT/
CD36 membrane localization and lipid accumulation were linked
in OBT2D myotubes. Palmitate uptake occurs through passive
diffusion and protein-mediated transport. Phloretin is a general
transport inhibitor [17]. We tested the possible influence of
phloretin (Fig. 2 E) prior to palmitate treatment. Phloretin
inhibited palmitate-induced lipid accumulation to a greater extend
in OBT2D cells than in control cells (278.467.3% versus
249.469.5%, p,0.05). We next tested the possible influence of
sulfo-N-succinimidyloleate (SSO), which specifically binds to
plasma membrane FAT/CD36, resulting in an arrest of the
transport function of this protein [18] (Fig. 2 F). Incubation of
Control and OBT2D differentiated cells with SSO inhibited
palmitate-induced lipid accumulation. Again, the inhibition was
significantly more pronounced in OBT2D cells than in Control
cells (246.663.7% versus 223.062.2%, p,0.05).
Increased translocation of FAT/CD36 in Control cells after
AMPK activation or insulin stimulation
To test whether translocation of FAT/CD36 in Control
myotubes could be increased, cells were acutely treated with
AMPK activators (AICAR and metformin (MET)) or insulin
(INS), two stimuli known to induce the translocation of FAT/
CD36 to the plasma membrane of muscle tissue [7] (Fig. 3 A).
Acute INS, AICAR or MET treatments induced FAT/CD36 cell
surface localization in Control myotubes. We also overexpressed a
constitutively activated form of AMPKalpha 2 subunit [19] in
Control cells. This constitutively activated form of AMPK alpha2
was well expressed and phosphorylated (Fig. 3 B). FAT/CD36
translocation (in red) in Control cells was observed after AMPK
alpha2 overexpression (Fig. 3 C) whereas FAT/CD36 was not
localized to the plasma membrane after infection with the empty
adenovirus (GFP).
AMPK activation by AICAR induced increased beta-
oxidation and no change in lipid accumulation in Control
cells
To determine whether increased translocation of FAT/CD36 in
Control myotubes was associated with increased lipid accumula-
tion, we tested the effect of acute AICAR stimulation alone or in
combination with specific FAT/CD36 inhibition (SSO) on lipid
accumulation. SSO treatment did not significantly reduce lipid
FAT/CD36 Regulation in Primary Human Muscle Cells
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induce increased lipid accumulation (Fig. 4 A). We also tested the
effect of expressing the constitutively activated form of AMPK
alpha 2 on lipid accumulation (Fig. 4 B) and found that Control
myotubes overexpressing AMPK alpha 2 did not show increased
positive oil red O cells. Lipid accumulation in myotubes is the
result of the balance between FA uptake, FA esterification and FA
oxidation. Since AMPK activation is known to induce increased
Figure 1. OBT2D myotubes are characterized by increased lipid accumulation and plasma membrane FAT/CD36 localization. A.
Quantification of lipid accumulation in Control (n=4) and OBT2D differentiated satellite cells (n=5) after palmitate treatment (0.6 mM for 16 h). Data
are presented normalized to lipid accumulation in Control myotubes. Each point was assayed in triplicate for each of the 9 independent cell cultures.
*, p,0.05, OBT2D versus Control differentiated cells. B. Representative immunofluorescence microscopy of satellite cells established from control
subjects (Control) and obese type 2 diabetic patients (OBT2D) after 8 days of differentiation. Living myotubes were incubated for 1 h with an
antibody against FAT/CD36 (H300, left panel) and for 1 h with an antibody against FAT/CD36 alexa 488 (CD36- alexa488, right panel). For H300
staining a polyclonal secondary antibody conjugated to alexa 488 (green) was added to the cells for 1 h. After fixation and permeabilization, cells
were incubated with an antibody against troponin T (TT) visualized using a secondary monoclonal antibody conjugated to alexa 546 (red). Nuclei in
cells were stained by dapi (blue). The 4 Control and the 5 OBT2D showed a staining similar to the representative pictures. Scale bar represents 30 mm.
C. Top panels: Western blot analysis of total FAT/CD36 and caveolin 3 expression in differentiated satellite cell lysate established from 4 control
subjects numbered 1 to 4 (Control) and 3 obese type 2 diabetic (OBT2D) patients numbered 1 to 3. Bottom panels: Western blot analysis of FAT/CD36
and caveolin 3 expression in post-membrane fractions (P) and plasma membrane fractions (Mb) of differentiated satellite cells established from 4
control subjects (1 to 4) and 3 obese type 2 diabetic (1 to 3) patients.
doi:10.1371/journal.pone.0028981.g001
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OBT2D myotubes. A. Representative light microscopy of myotubes derived from control subjects (Control) or obese type 2 diabetic patients
(OBT2D), after 8 days of differentiation, stained by oil red O after palmitate treatment (0.6 mM for 16 h). The 4 Control and the 5 OBT2D cells showed
a staining similar to the representative pictures. Arrows show reserve cells. Scale bar represents 30 mm. B. Merged picture of FAT/CD36 (H300),
troponin T (TT) and dapi staining in OBT2D differentiated cells (for 8 days). Living cells were incubated for 1 h with an antibody against FAT/CD36
(H300, left panel) and for 1 h with a polyclonal secondary antibody conjugated to alexa 488 (green). After fixation and permeabilization, cells were
incubated with an antibody against troponin T (TT) visualized using a secondary monoclonal antibody conjugated to alexa 546 (red). The 5 OBT2D
cells showed a staining similar to the representative pictures. Arrows show reserve cells. Scale bar represents 30 mm. C. Left panel: Western blot
analysis of the expression of total FAT/CD36 in proliferative (0), and after 2, 4, 6 and 8 days of differentiation of cells established from two control
subjects (Control 1 and 2) and two obese type 2 diabetic patients (OBT2D 1 and 2). Troponin T (TT) and caveolin 3 were used as markers of myotube
differentiation and a-tubulin as a loading control. Right panel: quantification by density analysis of the 2 controls and the 2 OBT2D. Data are
presented normalized to a-tubulin protein expression where the value of Control cells after 8 days of differentiation has been arbitrary chosen as the
reference value equal to 1. D. Representative immunofluorescence microscopy of cells established from obese type 2 diabetic patients (OBT2D) in
proliferative (0), and after 2, 4 and 8 days of differentiation, treated by palmitate (0.6 mM for 16 h), incubated for the last hour with CD36-alexa488
antibody (green) and stained by oil red O (red) after fixation. The 5 OBT2D cells showed a staining similar to the representative pictures. Scale bar
represents 30 mm. E. Percentage of inhibition of lipid content in Control (n=4) and in OBT2D differentiated satellite cells (n=5) after phloretin
stimulation (400 mM for 30 min) followed by palmitate treatment (0.6 mM for 16 h). Data are means 6SEM. Each point was assayed in triplicate for
each of the 9 independent cell cultures. *, p,0.05, OBT2D versus Control cells. F. Percentage of inhibition of lipid content in Control (n=4) and
OBT2D differentiated satellite cells (n=4) after SSO stimulation (250 mg/ml for 30 min) followed by three PBS washes and by palmitate treatment
(0.6 mM for 16 h). Data are means 6SEM. Each point was assayed in triplicate for each of the 8 independent cell cultures. *, p,0.05, OBT2D versus
Control cells.
doi:10.1371/journal.pone.0028981.g002
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before and after AICAR stimulation in Control cells. As shown on
figure 4 C, beta-oxidation was significantly increased by acute
AICAR treatment (p,0.05).
FAT/CD36 is not associated with lipid rafts in OBT2D
myotubes
In order to gain insight into mechanisms of FAT/CD36
localization in OBT2D myotubes, we examined intracellular
staining of FAT/CD36 (after fixation and permeabilization) in
Control and OBT2D muscle cells. Intracellular FAT/CD36
appeared similar between Control and OBT2D cells when using
the two antibodies directed against FAT/CD36, H300 (Fig. 5 A,
left panel) and CD36-alexa488 (Fig. 5 A, right panel). Moreover,
intracellular FAT/CD36 was observed in both differentiated cells
(troponin T positive) and reserve cells (arrows). In adipocytes,
FAT/CD36 has been found in lipid rafts and caveolae [21],
suggesting that lipid rafts regulate the expression and function of
FAT/CD36 at the level of the plasma membrane. Lipid rafts are
composed of DRMs (detergent resistant-membranes). Isolation of
DRMs was performed in order to compare lipid rafts between
Control and OBT2D differentiated cells. Caveolin 3 expression
was used to monitor DRMs purification and the molecular
chaperone binding protein (BIP) as an endoplasmic reticulum
marker excluded from DRMs. As shown on Figure 5 B, caveolin 3
expression was variable between cells (Control 1, Control 2,
OBT2D 1 and OBT2D 2) but was mainly found in fractions 3
and/or 4 (identified as DRMs) in Control and in OBT2D
differentiated cells. Extraction with Triton X-100 yielded good
separation of lipid rafts from BIP, as it was not detected in DRM
fractions. The association of FAT/CD36 with lipid rafts was then
analyzed. Surprisingly, FAT/CD36 expression was only detected
Figure 3. AMPK activation increases FAT/CD36 translocation in Control myotubes. A. Representative immunofluorescence microscopy of
myotubes established from control subjects (Control) after 8 days of differentiation, incubated for 1 h at 37uC with CD36-alexa488 antibody (green)
followed by insulin stimulation (100 nM for 10 min) or by AICAR stimulation (500 mM for 1 h) or by metformin stimulation (2 mM for 1 h). Nuclei were
stained by dapi (blue) after fixation of the cells. The 4 Control cells showed a staining similar to the representative pictures. Scale bar represents
30 mm. B. Western blot analysis of the expression of AMPK and the phosphorylated form of AMPK (PAMPK) after infection with an adenovirus
expressing either GFP (GFP) or GFP and the constitutively activated form of AMPK alpha 2 (alpha 2) in differentiated cells established from control
subjects (Control). C. Representative immunofluorescence microscopy of myotubes established from control subjects (Control) after 8 days of
differentiation infected with an adenovirus expressing either GFP (GFP) or GFP and the constitutively activated form of AMPK alpha 2 (alpha 2). To
monitor cell surface FAT/CD36 localization in a co-staining experiment, CD36-alexa488 antibody (green) could not be used because of the GFP
expression, as such, the same antibody against FAT/CD36 was used but with PhytoErythrine (CD36-PE) as a red fluorochrome. Living cells were
incubated for 1 h with CD36- PE (red). Nuclei in cells were stained by dapi (blue). Scale bar represents 30 mm.
doi:10.1371/journal.pone.0028981.g003
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accumulation in Control (n=4) (A) after palmitate treatment (0.6 mM for 16 h) or palmitate treatment plus AICAR stimulation (500 mM for 1 h) or
palmitate treatment after SSO addition (250 mg/ml for 30 min) or palmitate treatment with or without AICAR stimulation after SSO addition. Data are
means 6SEM. Each point was assayed in triplicate for each of the 4 independent cell cultures. B. Representative fluorescence and light microscopy of
myotubes established from control subjects (Control) and from obese type 2 diabetic patients (OBT2D) after 8 days of differentiation infected with an
adenovirus expressing either GFP (GFP) or GFP and the constitutively activated form of AMPK alpha 2 (alpha 2) stained by oil red O (ORO) after
palmitate treatment (0.6 mM for 16 h). C. Palmitate beta-oxidation in differentiated Control cells (n=3) before (2) and after (+) AICAR stimulation
(500 mM for 1 h) expressed relative to protein content. Experiments were performed in triplicate for each of the 3 independent cell cultures. Data are
mean 6SEM. *, P,0.05, AICAR-treated versus untreated Control cells.
doi:10.1371/journal.pone.0028981.g004
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but not in DRMs fractions showing that FAT/CD36 is not
associated with lipid rafts in primary human myotubes.
Increased FAT/CD36 cycling in OBT2D myotubes
In order to monitor the dynamic of FAT/CD36 cycling, we
performed immunofluorescence staining of FAT/CD36 in living
cells by incubating CD36-alexa488 antibody for different periods
of time (15 min, 1 h and 16 h). Incubation of living Control cells
with CD36-alexa 488 antibody only showed important cell surface
FAT/CD36 staining after 16 h (Fig. 6 A, top panels). Conversely,
cell surface FAT/CD36 was already detected in OBT2D
myotubes after 15 min of incubation and was independent of
incubation time (Fig. 6 A, bottom panels). We incubated CD36-
alexa488 at a lower temperature (room temperature, 22uC) to
reduce the rate of FAT/CD36 cycling in OBT2D myotubes. As
shown on Figure 6 B, cell surface FAT/CD36 was no longer
detected in OBT2D myotubes after 15 min of incubation with the
Figure 5. Plasma membrane FAT/CD36 is not associated to lipid raft in OBT2D myotubes. A. Representative immunofluorescence
microscopy of satellite cells established from control subjects (Control) and obese type 2 diabetic patients (OBT2D) after 8 days of differentiation,
incubated after fixation and permeabilization with antibodies against FAT/CD36 (H300, left panel and CD36- alexa488, right panel) and against
troponin T (TT). A polyclonal secondary antibody conjugated to alexa 488 (green) was used to visualize H300 and a secondary monoclonal antibody
conjugated to alexa 546 (red) to visualize troponin T. Nuclei in cells were stained by dapi (blue). The 4 Control and the 5 OBT2D cells showed a
staining similar to the representative pictures. Arrows show reserve cells. Scale bar represents 30 mm. B. Differentiated satellite cells derived from two
control subjects (Control 1 and 2) (left panels) and from two obese type 2 diabetic patients (OBT2D 1 and 2) (right panels) were lysed in 1% Triton and
subjected to flotation sucrose density gradient centrifugation. Equal volumes of each fraction (1 to 10) were analyzed by western blotting with
antibodies against BIP and caveolin 3. Caveolin 3 mark detergent resistant membranes (lipid rafts) fractions. Non-raft proteins resident in the
endoplasmic reticulum (BIP) are recovered in heavier fractions. C. Same experiment as in (B) using BIP, caveolin 3 and FAT/CD36 (H300) antibodies.
The 4 Control and the 5 OBT2D cell cultures showed a FAT/CD36 expression similar to the representative Western blots.
doi:10.1371/journal.pone.0028981.g005
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OBT2D myotubes in the medium were responsible for FAT/
CD36 cycling, we tested supernatant of OBT2D differentiated
cells on Control differentiated cells (Fig. 6 C). Interestingly,
supernatants from two different OBT2D differentiated cells
(OBT2D1 and OBT2D2) increased cell surface FAT/CD36 in
two different Control differentiated cells (Control 1 and Control 2).
Discussion
Primary human muscle cells represent a good model for
studying molecular mechanisms involved in type 2
diabetes
Primary human satellite cells have been shown to display the
majority of the defects previously described for type 2 diabetic
muscle in vivo including defective insulin signaling pathway
[10,11], reduced insulin-stimulated glycogen synthase and glucose
transport activities [22,23], and reduced lipid oxidation [24,25].
We have previously shown an abnormal cell surface FAT/CD36
localization [5] in cells derived from obese patients and an
abnormal metabolic flexibility in response to high palmitate
concentrations in myotubes derived from obese type 2 diabetic
patients [15]. In the present study we have obtained new
interesting results, which confirm that this cellular model can be
used to study mechanisms related to type 2 diabetes in human
skeletal muscle. By performing fractionation experiments, we were
able to show biochemically that using CD36-alexa 488 antibody in
living cells is a simple and powerful tool to follow cell surface
localization of FAT/CD36. Moreover, this tool can be used to test
molecules involved in FAT/CD36 translocation since we have
shown that signalling pathways (insulin and AMPK) involved in
FAT/CD36 translocation in the skeletal muscle [6,7] were also
able to induce endogenous FAT/CD36 translocation in Control
cells. A permanent relocation of FAT/CD36 was observed in the
skeletal muscle tissue of obese and T2D patients [4,5]. The term
permanent relocation was used since the increase in membrane-
associated FAT/CD36 [4,26] was accompanied by a decrease in
intracellular (vesicle-bound) FAT/CD36 and not by an increase in
total FAT/CD36 expression. In our study, we have shown that
total FAT/CD36 expression was not increased in OBT2D cells.
Cell surface FAT/CD36 was dependent upon duration of
antibody incubation. Control cells presented a slow cycling rate
of FAT/CD36 and undetectable FAT/CD36 protein expression
in plasma membrane fractions under basal conditions compared to
OBT2D myotubes. Moreover decreasing the temperature at
which the experiment was performed decreased cell surface FAT/
CD36 in OBT2D myotubes consistent with a continuous cycling
of FAT/CD36. As such, the increase in sarcolemmal FAT/CD36
observed in the skeletal muscle of type 2 diabetic patients may
result from a continuous cycling of FAT/CD36 suggesting that
defects in both, endocytosis and exocytosis may be expected.
FAT/CD36 cycling was specific to myotubes and was not
observed in reserve cells despite the presence of intracellular
FAT/CD36. As such, we may suppose that FAT/CD36 cycling is
controlled by a system specific to differentiated cells. Moreover,
cell surface FAT/CD36 was observed in Control cells by
incubating these cells with supernatants from OBT2D differenti-
ated cells. This result implies that the appearance of cell surface
FAT/CD36 is dependent upon a secreted factor or a combination
of secreted factors or that a secreted factor inhibiting FAT/CD36
cycling is missing in differentiated OBT2D cell supernatant.
Recent papers [27,28] have shown by using proteomic approach-
es, that many proteins were secreted from human and mouse
skeletal muscle cells and that these secreted proteins were modified
in response to strength training or to TNF-alpha stimulation.
Moreover, skeletal muscle secretome is dynamic during differen-
tiation [29]. As such proteomic experiments should be performed
in differentiated Control and OBT2D myotubes in order to
Figure 6. FAT/CD36 is continuously cycling in OBT2D myo-
tubes. A. Representative immunofluorescence microscopy of myo-
tubes established from control subjects (Control) (top panels) and from
obese type 2 diabetic patients (OBT2D) (bottom panels) after 8 days of
differentiation, incubated on living cells for 15 min, 1 h and 16 h at
37uC with an antibody against FAT/CD36 alexa 488 (CD36- alexa488).
Nuclei in cells were stained by dapi (blue). The 4 Control and the 5
OBT2D showed a staining similar to the representative picture. Scale bar
represents 30 mm. B. Representative immunofluorescence microscopy
of myotubes established from obese type 2 diabetic patients (OBT2D)
after 8 days of differentiation, incubated on living cells for 15 min at
37uC and at 22uC with an antibody against FAT/CD36 alexa 488 (CD36-
alexa488). Nuclei in cells were stained by dapi (blue). The 5 OBT2D cells
showed a staining similar to the representative pictures. Scale bar
represents 30 mm. C. Representative immunofluorescence microscopy
of myotubes established from control subjects (Control 1 and Control 2)
after 7 days of differentiation, incubated overnight with supernatant
from OBT2D1 or OBT2D2 and for 1 h at 37uC with an antibody against
FAT/CD36 alexa 488 (CD36- alexa488). Nuclei in cells were stained by
dapi (blue). Scale bar represents 30 mm.
doi:10.1371/journal.pone.0028981.g006
FAT/CD36 Regulation in Primary Human Muscle Cells
PLoS ONE | www.plosone.org 8 December 2011 | Volume 6 | Issue 12 | e28981identify secreted proteins which could be responsible for increased
FAT/CD36 cycling during type 2 diabetes.
The importance of FAT/CD36 cycling in determining lipid
accumulation is different between OBT2D and Control
myotubes
In adipocytes, FAT/CD36 expression appeared to be closely
linked to preadipocyte differentiation [9]. Furthermore, FAT/
CD36-mediated long-chain fatty acid uptake in adipocytes has
been shown to require plasma membrane rafts [21]. In the present
study, we showed that this is not the case in primary human
muscle cells. As such, expression and localization of FAT/CD36
are differentially regulated during primary human muscle cell
differentiation and murine preadipocyte differentiation. The fact
that the proteins involved in fatty acids transport would differ in
adipocytes and muscle tissue is not surprising given their different
metabolic roles and physiological functions [30]. The precise
localization of cell surface FAT/CD36 in relation to other known
membrane proteins in primary human myotubes remains to be
determined.
Fractionation experiments showed that only a minor part of
FAT/CD36 was present in plasma membrane fractions implying
that under basal condition, FAT/CD36 is mainly localized in
intracellular compartments in OBT2D myotubes. Palmitate-
induced lipid accumulation was observed in OBT2D differentiated
cells with a concomitant cell surface FAT/CD36 localization.
Moreover, the increase in palmitate-induced lipid accumulation
observed in OBT2D myotubes was due to an increase in
transporter-mediated lipid entrance (phloretin inhibition) mainly
mediated by FAT/CD36 (SSO inhibition). Altogether these results
show that cell surface localization of FAT/CD36 in fully
differentiated OBT2D cells allows lipid accumulation. However,
the more pronounced inhibition of lipid accumulation with
phloretin (by 78%) compared to SSO treatment (by 47%) suggests
that other lipid transporters may also be involved. This is consistent
with the notion that membrane fatty acid binding protein
contributes to fatty acid transport with FAT/CD36 [31,32].
Acute AICAR or metformin treatment induces FAT/CD36
translocation in Control myotubes. This result was similar when
using an adenovirus overexpressing a constitutively active form of
AMPK, suggesting that FAT/CD36 translocation in response to
AICAR or metformin treatment was due to AMPK activation. We
hypothesized that similarly to OBT2D myotubes, increased FAT/
CD36 translocation in Control myotubes would lead to increased
lipid accumulation. However, inducing FAT/CD36 translocation
in Control cells had no effect on lipid accumulation since AMPK
activation in Control cells was able to significantly increase
mitochondrial beta-oxidation. As such, increased translocation of
FAT/CD36 in Control cells is not sufficient to induce lipid
accumulation. We know from a previous work [15] that cells
derived from obese type 2 diabetic patients display an impaired
capacity to respond to metabolic stimuli at the level of
mitochondrial activity, which could explain the difference in lipid
content between OBT2D and Control cells even when control
cells showed a similar cell surface FAT/CD36 content than
OBT2D cells. Moreover, protein-mediated lipid transport was not
the major mechanism responsible for palmitate-induced lipid
accumulation in Control myotubes (less than 50% of inhibition by
phloretin).
Conclusion
This study is the first to show that increased lipid accumulation
in OBT2D myotubes results from increased FAT/CD36 cycling.
We propose that lipid content in Control myotubes may mostly be
influenced by catabolic pathways (lipolysis, fatty acid oxidation)
than anabolic pathways (uptake, esterification) in contrast to
myotubes derived from obese type 2 diabetic patients.
Materials and Methods
Primary human satellite cell culture
Skeletal muscle biopsy of the vastus lateralis was performed
according to the percutaneous Bergstro ¨m technique after local
anesthesia (xylocaine) [33,34]. The experimental protocol was
approved by ‘‘Le Comite ´ de Protection de Personnes (CPP) «Sud
Me ´diterrane ´e IV»» (03/10/GESE, Montpellier, France). In-
formed and written consent was obtained from all subjects after
explanation of the protocol. In the present study, biopsies were
taken from four control subjects (control, age: 49.262.7 years,
body mass index: 24.061.2 kg/m
2) with no familial or personal
history of diabetes and from five obese type 2 diabetic patients
(OBT2D, age: 53.462.4 years, body mass index: 31.560.6 kg/
m
2). Clinical characteristics of the subjects were previously
described [5]. The number of cell cultures used in this study is
not high, however these cells were isolated from homogeneous
populations of male subjects matched by age and physical activity
[5]. Type 2 diabetic patients are obese since we have previously
shown that cells derived from non obese type 2 diabetic patients
did not show increased lipid accumulation compared to body mass
index matched healthy subjects [5]. Cell culture of primary human
satellite cells was performed as previously described [5,12,15,35],
cultures were maintained in a growth medium composed of
(DMEM, 10% fetal bovine serum (FBS) and 1% Ultroser G) and
when myoblasts reached confluence, medium was changed to
differentiation medium (growth medium minus Ultroser G) and
the differentiation process occurred until fusion and terminal
differentiation into contractile myotubes (8 days). The experiments
were performed on passages 2 to 4.
Immunofluorescence
For intracellular staining, differentiated satellite cells were fixed
with paraformaldehyde at 4% in PBS for 10 min, permeabilized
with 0.5% triton in PBS for 2 min, saturated with 0.5% BSA in
PBS for 10 min and then incubated with primary antibodies
against troponin T diluted at 1/500 (Sigma, Saint-Quentin
Fallavier, France), or polyclonal anti-CD36 diluted at 1/100
(H300, sc-9154, Tebu-BIO, Le Perray en Yvelines, France) or
monoclonal anti-CD36 Alexa fluor 488 diluted at 1/100 (SM,
Tebu-BIO, Le Perray en Yvelines, France). The antibody against
FAT/CD36 (H300, sc-9154) was previously characterized on
human skeletal muscle tissue and cells [5,36,37,38,39,40]and the
monoclonal anti-CD36 Alexa fluor 488 (SM, Tebu-BIO) was
previously characterized in [5]. For troponin T staining, the
secondary antibody was an anti-mouse coupled to Alexa 546
diluted at 1/1000 (GE Healthcare, Orsay, France) and for anti-
CD36 (H300) an anti-rabbit coupled to Alexa 488 diluted at 1/
1000 (GE Healthcare, Orsay, France).
FAT/CD36 has an extracellular loop allowing performing
immunofluorescence in living cells by adding the antibody directly
to the culture medium (FAT/CD36 staining in living cells can only
be detected when the transporter is at the plasma membrane). We
have used primary antibodies (SM) already coupled to fluoro-
chrome (alexa 488 or PhytoErythrine) to avoid using a secondary
antibody. Briefly, cells were washed with PBS and anti-CD36
Alexa Fluor 488 (SM) antibody was added at a dilution of 1/500 in
PBS 2% BSA for 15 min, 1 h or 16 h either at 37uC or at room
temperature (22uC) prior to paraformaldehyde fixation. For co-
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ytrhine (CD36-PE, SM, Tebu-BIO) diluted at 1/500 was used
instead of anti-CD36 Alexa fluor 488 (CD36-Alexa 488, SM,
Tebu-BIO) (Fig. 3C).
For Figure 6C, medium from two independent differentiated
Control (Control 1 and Control 2) cell cultures (day 7) was
replaced by 1 ml of supernatant from two independent differen-
tiated OBT2D (OBT2D 1 and OBT2D 2) cell cultures (Day 8) for
16 hours prior to staining on living cells with CD36 alexa 488.
Virus infection
Adenovirus overexpressing a constitutively active truncated
(40 kDa) form of AMPKa2 was previously described [19].
Infection of myotubes with either the empty adenovirus (GFP)
or the adenovirus overexpressing the constitutively active form of
AMPK alpha 2 (alpha 2) was performed on Day 6, 48 hours prior
to the end of myotube differentiation.
Fatty acid preparation and cells treatments
Stock solution (0.6 M) of palmitate was prepared. Palmitate was
dissolved in chloroform. Samples were stored at 220uC until
required. Fatty acid stocks were diluted to 0.6 mM in DMEM
containing 10% FBS (differentiation medium) and added to the
differentiated satellite cells. Control satellite cells were incubated in
DMEM containing 10% FBS and 0,001% chloroform without
palmitate as previously described [5,12,15]. Treatments per-
formed on differentiated satellite cells are detailed in the figure
legends and were realized in triplicate for each of the 9
independent cell cultures. The following reagents were purchased
from Sigma (Saint Quentin Fallavier, France): L-Glutamine,
DMEM, palmitate, phloretin, AMP-mimetic 5-aminoimidazole-
4-carboxamide-1-b-D-ribofuranoside (AICAR), metformin and
insulin. FBS was purchased from Hyclone (Brebieres, France)
and Sulfo-N-succinimidyloleate (SSO) was a kind gift from W.
Coumans (Maastricht, The Netherland).
Oil red O staining
Oil red O staining was carried for one hour followed by 2 or 3
washes with distilled water. Lipid droplets were then visualized by
light microscopy. In order to quantify lipid accumulation in
myotubes, oil red O was extracted using isopropanol. The
absorbance value was measured using a spectrophotometer set
at 490 nm [41] and blanked to untreated cells. Staining and
quantification of lipid accumulation in primary human satellite
cells were previously described [5,12,15]. For Figure 2 D,
conventional oil red O was modified according to the previously
described protocol [42].
Western Blots
Cellular extracts were quantified and lysed in Laemmli buffer.
30 mg of total proteins were transferred to nitro-cellulose
membranes (Schleicher and Schuell, Bioscience, Dassel, Ger-
many). Western blots were realized as previously described [8].
Following primary antibodies were used: anti-CD36 (H300, sc-
9154) at 1/200; anti-caveolin 3 at 1/1000 and anti-BIP at 1/
1000 (BD Biosciences, Le Pont de Claix, France); anti-troponin
Ta t1 / 5 0 0a n da n t i - a-tubulin at 1/1000 (Sigma Saint-Quentin
Fallavier, France); The secondary antibodies were anti-rabbit
and anti-mouse antibodies coupled to horseradish peroxydase
diluted at 1/5000 (GE Healthcare, Orsay, France). Proteins
were visualized using an enhanced luminescent reagent (Tebu-
BIO, Le Perray en Yvelines, France), and exposed to
autoradiograph film (GE Healthcare, Orsay, France). Expres-
sion of proteins was quantified by density analysis using ImageJ
Launcher Software.
Plasma membrane and post-plasma membrane fractions
One million of differentiated satellite cells derived from control
subjects (Control) and type 2 diabetic patients (OBT2D) were used
to prepare cell lysate, plasma membrane (Mb) and post-plasma
membrane fractions (P) as previously described [43].
Isolation of Detergent-Resistant Membranes (DRMs)
DRMs were prepared by detergent extraction of cellular
proteins and centrifugation over discontinuous sucrose gradients
essentially as described [44]. 4.5610
6 of differentiated satellite
cells derived from control subjects (Control) and from obese type
2 diabetic patients (OBT2D) were used to prepare the DRMs.
Cells were washed twice with ice-cold PBS and scraped into
667 ml of MBST buffer (25 mM MES, 150 mM NaCl, 1% Triton
X-100, protease inhibitors mixture (Roche, Rosny-sous-bois,
France) and homogenized with a loose fitting dunce homogenizer
(20 strokes). The extract was adjusted to 40% sucrose by the
addition of 667 ml of 80% sucrose in MBS lacking triton X-100
and placed in the bottom of an ultracentrifuge tube. A
discontinuous sucrose gradient was formed by overlaying this
solution with 1.33 ml of 38% sucrose and 1.33 ml of 5% sucrose
(both in MBS). The tubes were centrifuged at 40,000 rpm in an
SW60 Ti rotor for 16 h at 4uC, and 10 fractions (numbered 1 to
10) of 400 ml were collected manually from the top of the
gradient, resuspended in Laemmli buffer and subjected to SDS-
PAGE on 10% acrylamide gels followed by Western blot
analyses.
Palmitate oxidation
Control cells were cultured in 96-well plates and differentiated.
Differentiated satellite cells were exposed or not to cold palmitate
(0.6 mM) for the last 16 h of differentiation and then exposed to
differentiation medium (DMEM+10% FBS) supplemented with
1% BSA, 50 mM palmitate and 9.5 mM (0,09 mCi) [1-
14C]palmi-
tate. Identical incubations were conducted on parallel plates that
contained no cells. Palmitate oxidation rates were determined by
measuring production of
14C-labeled acid-soluble metabolites
(ASM), a measure of tricarboxylic acid cycle intermediates and
acetyl esters. After incubation for 30 min at 37uC, reactions were
terminated by aspiration of the media and addition of 100 mlo f
HClO4 at 5% for 15 min at room temperature. The ASM were
assayed in supernatants of the acid precipitate. Radioactivity of
ASM was determined by liquid scintillation counting by use of
4.5 ml of liquid scintillation cocktail (Optiphase ‘Hisafe’ 3, Perkin
Elmer) in scintillation vials. For protein determination, identical
incubations were conducted on parallel plates with the same
number of cells.
Statistical analysis
Statistical analyses were performed using Statview 5.0. Data are
shown as mean 6 SEM. Statistical analyses were performed using
Student’s t test for unpaired and paired comparison, or ANOVA
with Fisher’s PLSD post-hoc test for multiple comparisons.
P,0.05 was considered to be significant.
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